These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30963514)

  • 21. Dopamine agonists versus levodopa monotherapy in early Parkinson's disease for the potential risks of motor complications: A network meta-analysis.
    Zhang Q; Chen X; Chen F; Wen S; Zhou C
    Eur J Pharmacol; 2023 Sep; 954():175884. PubMed ID: 37385577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease.
    Zhou CQ; Zhang JW; Wang M; Peng GG
    J Clin Neurosci; 2014 Jul; 21(7):1094-101. PubMed ID: 24786715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M; Samii A; Takkouche B; Rochon PA
    Drug Saf; 2001; 24(11):863-8. PubMed ID: 11665873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.
    Giménez-Roldán S; Esteban EM; Mateo D
    Clin Neuropharmacol; 2001; 24(6):346-51. PubMed ID: 11801810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
    Zhuo C; Zhu X; Jiang R; Ji F; Su Z; Xue R; Zhou Y
    Sci Rep; 2017 Apr; 8():45865. PubMed ID: 28374775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease.
    Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Zhu R; Li J; Hu J; Cai M
    Curr Med Res Opin; 2015 Apr; 31(4):723-30. PubMed ID: 25586298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
    Xiang W; Sun YQ; Teoh HC
    Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study.
    Zhang Z; Wang J; Zhang X; Chen S; Wang Z; Zhang B; Liu C; Qu Q; Cheng Y; Li J; Cao H; Cai M; Zhu R
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1022-6. PubMed ID: 23932066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
    Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
    Mizuno Y; Nomoto M; Hasegawa K; Hattori N; Kondo T; Murata M; Takeuchi M; Takahashi M; Tomida T;
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1388-93. PubMed ID: 25455692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pramipexole for levodopa-induced complications in Parkinson's disease.
    Clarke C E; Speller J M; Clarke J A
    Cochrane Database Syst Rev; 2000; 2000(3):CD002261. PubMed ID: 10908540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.